Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

CHICAGO, March 11, 2026 -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative.

Following this purchase, Cosmos Health’s total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum.

Greg Siokas, CEO of Cosmos Health, stated: "We continue to view select digital assets as an attractive asset class with strong upside potential. Our growing position in Bitcoin and Ethereum reflects a disciplined treasury strategy designed to enhance balance sheet diversification while maintaining financial flexibility. As we continue to expand our core healthcare operations and execute on our broader growth strategy, we believe selectively allocating capital to digital assets can complement our balance sheet and create additional value for shareholders.

At the same time, if the market does not fully recognize the intrinsic value of our Company, these digital assets provide additional financial flexibility and may be monetized to help address the current discount to book value and support initiatives that enhance shareholder value.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK.